Adamis announces partner Sandoz’s U.S. launch of Symjepi

Adamis announces partner Sandoz’s U.S. launch of Symjepi  Adamis Pharmaceuticals Corporation () announced that its marketing and commercial partner, Sandoz, a Novartis (NVS) division, has launched Symjepi 0.3 mg Injection in the U.S. market for the emergency treatment of allergic reactions, including anaphylaxis. Sandoz is launching this medicine as an affordable, single-dose, pre-filled syringe alternative to epinephrine auto-injectors. Symjepi will be rolled out via a phased launch and will initially be available in the institutional setting, an established channel where Sandoz has significant experience and knowledge, followed by introduction into the retail market.
https://thefly.com/landingPageNews.php?id=2849915